Under a tenth of individuals that would benefit from obesity jabs including Wegovy can access them, warns the World Health Organization as it publishes its inaugural advice on the therapies.
Considering over a billion people worldwide now living with obesity, it is calling for increased and just availability to this class of drugs.
According to estimates, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"Our new guidelines affirms that obesity is a long-term condition that can be treated with comprehensive and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant barriers to universal access to the injections that can aid individuals in losing significant body mass, explains the organization.
Skinny Jab Supply Crisis
Even under the present most optimistic outlook, the production of these medications would only suffice for around 100 million people – less than 10% of eligible patients, as stated by the WHO.
The advice encourages governments and firms to widen access, through approaches including licensing agreements.
A patent on the active ingredient – the main ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Obesity Injections Work
The injections replicate a natural hormone to delay gastric emptying, suppress the appetite and enhance feelings of fullness so individuals consume fewer calories.
People typically begin shedding pounds within a few weeks of starting on the weekly injections.
Evidence indicates users may put most of the weight back on within a year of stopping the medication, because their normal appetite come back.
To be carrying excess weight elevates your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and certain cancers.
Obesity impacts individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
